Drug intelligence / Profile preview

lan zhaketong

Development stage: Unknown
Lead developer: Sichuan Pearl Pharmaceutical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Lan Zhaketong (蓝楂酮苷) is a botanical-derived pharmaceutical candidate developed by Sichuan Pearl Pharmaceutical for the treatment of hyperlipidemia. It is specifically indicated for patients exhibiting the 'phlegm-turbidity' pattern according to Traditional Chinese Medicine (TCM) diagnostics. The drug is a flavonoid glycoside formulation, likely extracted from medicinal plants such as Hawthorn (Crataegus), which are traditionally used for cardiovascular health. Lan Zhaketong has been investigated in Phase 2 clinical trials in China (notably CTR20130234) to evaluate its efficacy in reducing blood lipid levels and its safety profile compared to placebo.

Other names: 蓝楂酮苷Lan Zhaketong capsule蓝楂酮苷胶囊

Beyond the preview

Go deeper on lan zhaketong.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lan zhaketong.

Explore the full profile